A practical 2-day In-house seminar focusing on the key legal and commercial challenges to achieving a successful collaboration agreement in the pharma, biotech and life sciences sector
Pharmaceutical and biotech companies are turning with increasing frequency to R&D and collaboration agreements – for pharmaceutical companies to put new products in their pipelines and for biotech companies to access the resources needed for final stage development, clinical trials, manufacturing and distribution.
This new In-house seminar from Falconbury offers you a unique opportunity to learn from an expert faculty to tackle the key challenges that arise when negotiating and drafting these agreements. It will enable you to draft effective watertight agreements and create the foundation to build long lasting and profitable relationships.
Includes a case study exercise and group discussion to ensure a complete learning experience.
The key objectives of this seminar
By attending this seminar, you will:
• EXAMINE how to make the right deal and find the right partner
• UNDERSTAND more about the due diligence process which is a key element for successful contracts
• LEARN more about the key terms of R&D and collaboration agreements
• FAMILIARISE yourself with the different ways of allocating ownership of IP and the problems and solutions of joint ownership
• GAIN knowledge of the regulatory regime affecting patents and R&D
• GET-TO-GRIPS with the legal structures and special features of business-to-business collaborations
• LEARN about the unique features of industry/ university collaborations including the typical contractual arrangements
• UPDATE yourself with the latest developments of EU competition law aspects
Who should attend?
From R&D, clinical, regulatory, commercial, sales and marketing, manufacturing, distribution and purchasing functions, including:
• Commercial and contract managers
• Business development managers
• In-house counsel
• Heads of legal departments
• Legal advisors
• Patent, IP, trademarks or licensing counsel
EU competition law – CASE STUDY
Delegates will be divided into small groups and given a case study based on latest EU developments.
Mark Anderson is a solicitor and former barrister, who established his law firm, Anderson & Company, in 1994. His clients are mostly technology-based companies and universities in the UK and Northern Europe. At the date of writing, he has advised 17 of the current members of the UK BioIndustry Association, and participated in negotiations with 20 other members (not his clients). He specialises in drafting, negotiating and advising on commercial contracts, particularly those which are concerned with intellectual property. He is the author of several legal textbooks, published by Oxford University Press, Butterworths, Tottel and the Law Society.
Laura Anderson is a Partner at Bristows in London. Since joining Bristows 12 years ago, Laura has specialised in non-contentious IP matters. She has considerable experience of commercial arrangements relating to the development and exploitation of all kinds of intellectual property rights. Laura has expertise in the competition law aspects of commercial IP transactions and has spent time working in Brussels, both at the EU Council of Ministers and in private practice. Laura acts for clients across a range of sectors including life sciences.
Dr. jur. Christian Czychowski is an Attorney at Law, Certified Information Technology Lawyer, Certified Copyright and Media Lawyer, admitted at the European Trade Mark Office, Partner in the Berlin office of Boehmert & Boehmert. He is a co-editor of the Manual of Intellectual Property in the Internet, a co-author of the Manual of Copyright and has specialised in IT law, copyright law, cyberlaw and licensing. He has worked for Boehmert & Boehmert since 1997 (since 2002 as a partner) in their Berlin office. He holds lectures at the University of Potsdam and is electedmember of the Committee for Copyright and Publishing Rights of the German Society of Industrial Property and Copyright (GRUR).
Patrick Duxbury is IP Partner and head of the six-partner Life Sciences Sector Team at Wragge & Co. The team delivers a unique mix of regulatory, anti-trust, IP, corporate and dispute resolution advice to many of the sector’s key players.
Susan Singleton is a solicitor with her own London firm, Singletons, which specialises in intellectual property law, including trade marks and competition law and Internet law and general commercial law. Articled at Nabarro Nathanson, she joined Slaughter and May’s EC/Competition Law Department on qualifying in 1985, moving to Bristows in March 1988, where she remained until founding her own firm in 1994. Since then she has advised over 410 clients. In 2002 she acted for the claimant in the first damages action for breach of the EU competition rules to come before the English courts Arkin v Borchard and Others.
Lindsey Woolley is Partner and Patent Attorney at Mewburn Ellis LLP, which she joined in 2002. Lindsey deals mainly with drafting and prosecution work and advises on portfolio management of interrelated patent families. Lindsey also deals with patent work in the biotechnology field, in particular molecular biology, biochemistry and biotechnology. Her clients include universities, research institutions and biotechnology companies. Lindsey has a degree in plant sciences from the University of Cambridge.
Tim Worden is an Associate in the Intellectual Property Department of Taylor Wessing. His practice includes both non-contentious and contentious intellectual property and he specialises in the life sciences and healthcare sectors. Tim was previously Legal Counsel and Company Secretary at Eli Lilly and Company Limited, the UK subsidiary of the US pharmaceutical company.